Investor Relations

NeoGenomics Releases Inaugural ESG Report

Company Overview

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma
Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, and United Kingdom. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States and Europe. 

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts


NeoGenomics, Inc.
9490 NeoGenomics Way
Fort Myers, FL 33912
T: 239-768-0600
F: 239-690-4237

Investor Relations

Kendra Sweeney
Investor Relations and ESG
T: 239-877-7474

Transfer Agent

Broadridge Shareholder Services
1155 Long Island Avenue
Edgewood, NY 11717-8309
T: (888) 789-8606